Category Archives: AAO

Dr. Pravin U. Dugel: Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

October 27, 2018 10:09 ET | Source:  Novartis International AG Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness demonstrated at year one were reaffirmed at year two with brolucizumab 6 mg versus aflibercept Robust visual gains shown in… Read More »

Retina Sub-day AAO 2015 – Day 2 – Las Vegas, Nevada

Dr. Sachin Mehta Reports from AAO Retina Subday – Day 2 Dr. Jay Duker reported on the use of a relatively new diagnostic imaging modality: optical coherence tomography angiography (OCT-A). OCT-A is a non-invasive imaging modality that uses motion contrast between OCT images in order to generate volumetric angiograms.  The retinal and choroidal vasculature can… Read More »